Home > Insider Trading > Filing (0001363213-15-000004)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
880771	Sciclone Pharmaceuticals Inc	SCLN	Pharmaceutical Preparations (2834)	943116852

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1363213	Friedhelm Blobel	950 Tower Lane, Suite 900 Foster City CA 94404	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2015-05-14	3,661	$9.13	163,991	No	4	F	Direct
Common Stock	Disposition	2015-05-14	1,315	$9.13	162,676	No	4	F	Direct
Common Stock	Disposition	2015-05-14	30,220	$9.13	132,456	No	4	F	Direct
Common Stock	Acquisiton	2015-05-14	80,517	$0.00	212,973	No	4	M	Direct
Common Stock	Acquisiton	2015-05-15	10,000	$2.49	222,973	No	4	M	Direct
Common Stock	Disposition	2015-05-15	10,000	$0.00	212,973	No	4	S	Direct
Common Stock	Disposition	2015-05-15	11,700	$0.00	201,273	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	F	Direct
No	4	F	Direct
No	4	F	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2015-05-15	10,000	$0.00	10,000	$2.49
Common Stock	Restricted Stock Unit	Disposition	2015-05-14	3,500	$0.00	3,500	$0.00
Common Stock	Restricted Stock Unit	Disposition	2015-05-14	70,000	$0.00	70,000	$0.00
Common Stock	Restricted Stock Unit	Disposition	2015-05-14	7,017	$0.00	7,017	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
709,360	2016-06-02	No	4	M	Direct
400,517		No	4	M	Direct
330,517		No	4	M	Direct
323,500		No	4	M	Direct

Footnotes

Shares disposed represent shares withheld to cover withholding tax obligations in connection with the vesting of Restricted Stock Units.
The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2014.
Granted under the Issuer's 2005 Equity Incentive Plan.
Provided the reporting person remains employed by or acting as a consultant to the Company, the option will become exercisable in four equal annual installments on 6/02/07, 6/02/08, 6/02/09 and 6/02/10.
Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock.
50% of the restricted stock units will vest on February 20, 2015 and 50% will vest on February 20, 2016, unless the trading window is closed for the Reporting Person on that date, then the vesting date will be deferred until the next date that the trading window is open.
100% of the restricted stock units will vest on March 14, 2015, unless the trading window is closed for the Reporting Person on that date, then the vesting date will be deferred until the next date that the trading window is open.
25% of the restricted stock units will vest on May 14, 2012, August 9, 2013, April 5, 2014, and April 5, 2015, unless the trading window is closed for the Reporting Person on that date, then the vesting date will be deferred until the next date that the trading window is open.